Singaporean startup Mesh Bio has raised $3.5 million in a Collection A funding spherical led by East Ventures. The spherical was additionally participated by Elev8, Seed Capitals, and its different shareholders.
WHAT IT’S FOR
In a press release, the corporate mentioned it would use its contemporary funds to scale the deployment of its options, significantly its flagship digital twin providing, throughout Hong Kong and Southeast Asia.
The World Well being Group revealed in 2019 that 76% of all deaths within the area have been attributed to noncommunicable ailments reminiscent of coronary heart ailments and diabetes. Mesh Bio has a focused deal with each Indonesia and the Philippines the place persistent ailments are mentioned to be most prevalent and lethal. “Southeast Asia presents myriad unmet healthcare wants, and our focus is to deal with these gaps successfully,” mentioned CEO and co-founder Dr. Andrew Wu.
THE LARGER TREND
The most recent funding increase comes three months after Mesh Bio secured a regulatory clearance from Singapore’s Well being Sciences Authority for HealthVector Diabetes. The digital twin-based software-as-a-medical system can predict a 3-year onset threat of persistent kidney illness in sufferers with kind 2 diabetes through the use of medical information pulled from hospital EMRs.
The digital twin resolution, which is an expanded providing on Mesh Bio’s DARA Well being Intelligence Platform, is now being trialled at Singapore Common Hospital, Tan Tock Seng Hospital, and chosen polyclinics in Singapore.
The event of HealthVector Diabetes was first reported in October.
